All KOL Pulse conferences
Post-Conference Intelligence · May 30 – Jun 3, 2025

ASCO 2025

Chicago, IL — top KOL voices, trial buzz, and themes pulled from verified physician social.
1,433Physician tweets
319Unique KOLs
3.6MTotal impressions
KOL Voices

Who moved the needle at ASCO 2025

Top physician voices ranked by impressions. Institutional / media accounts excluded.

Emerging Themes

What KOLs were talking about

Click any theme to see the top tweets that matched.

Dr Amol Akhade
@suyogcancer
Top 10 GI Trials – ASCO 2025 The biggest GI breakthroughs you must track this year! 🧬 ATOMIC – Atezolizumab + FOLFOX in stage III MSI-H colon 🛡️ MATTERHORN – Durvalumab + FLOT in gastric/GEJ 🧪 DYNAMIC-III – ctDNA-guided chemo in colon 💉 DESTINY-Gastric04 – T-DXd vs RAM+PTX https://t.co/QzeejEy9RN
26.5K impressions
gilberto lopes
@glopesmd
Join us at the rapid oral session in developmental therapeutics We are showing our experience with ctRNA added to ctDNA in liquid biopsy 1000+ samples - detection of fusions increased by 36% @asco #asco25 @GlopesMd @SylvesterCancer @LucenceHealth @OncBrothers @OncoAlert https://t…
15.1K impressions
Jun Gong
@jgong15
Lot of discussion to surely follow the DYNAMIC-III #ASCO25 oral. For rand trials of ctDNA-guided adj therapy in colon cancer to date: ➕trials DYNAMIC, CALGB 80702 (post-hoc) ➖DYNAMIC III, ALTAIR, COBRA Where do we go from here? @OncoAlert @IbrahimSahinMD1 @guildsman @ASCO https://t.co/psdUyvgDi2
14.0K impressions
Arndt Vogel
@arndtvogel
ctDNA-guided adj CTx escalation in stage III CRC #ASCO25 🔎Primary analysis of the ctDNA-positive cohort from the randomized AGITG DYNAMIC-III trial 👉mRFS 29 vs 36 mo 👉CTx escalation does not improve outcome 🧐 ctDNA very helpful to understand risk groups, but we need better https://t.co/HS5M9xzjqA
11.6K impressions
Oncology Brothers
@oncbrothers
Day 1 #ASCO25 highlights: 1. Review on recent approvals 2. #BREAKWATER (update): BRAF+ mCRC 3. #CM8HW (update): MSI-H mCRC 4. #DYNAMIC: ctDNA in colon ca 5. #CAIRO6: periOP Rx in peritoneal mets #OncTwitter @ASCO 1/6 https://t.co/4WaYxe1C…
8.3K impressions
Pashtoon Kasi MD, MS
@pashtoonkasi
#ASCO25 While #ctDNA🧬🩸is one of the strongest prognostic factor, the escalation strategy needs to be beyond just the addition of more chemo (upfront irinotecan - triplet FOLFOXIRI). 27% positive in both arms. 💡More duration of chemo/more chemo not the answer. @OncoAlert https://t.co/cJtTZWAj6n
6.5K impressions
Paolo Tarantino
@ptarantinomd
The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data. https://t.co/oNrmRNes0y
30.8K impressions
Dr Amol Akhade
@suyogcancer
Top 10 Breast Cancer Trials to Watch at #ASCO25 Save the date ⏰ Big data in HER2+, TNBC & HR+ mBC! 1️⃣ DESTINY-Breast09 – T-DXd+P vs THP (1L HER2+ MBC) [LBA] 2️⃣ ASCENT-04 – SG+pembro vs chemo+pembro (1L TNBC) [LBA] 3️⃣ SERENA-6 – Camizestrant+CDK4/6i in ESR1mut HR+ ABC [LBA] 4️⃣ https://t.co/XFoBMbN7ab
19.9K impressions
OncoAlert
@oncoalert
The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 ⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB https://t.co/OEnYjYzvAN
19.8K impressions
Dr Sarah Sammons
@drsarahsam
Destiny-Breast-09 will likely establish a new first-line therapy for HER2+ MBC. Here are my considerations going into #ASCO25 Patient population considerations: 1) De novo patients (capped at 50%): these patients are more likely to respond durably and possibly even be cured in
15.3K impressions
NEJM
@nejm
Original Article: Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer (DESTINY-Gastric04 phase 3 trial) https://t.co/1HxEBJ8jvi #ASCO25 | @ASCO https://t.co/XMJSKDt2AM
14.8K impressions
Paolo Tarantino
@ptarantinomd
Nick Turner presents OS results from INAVO120. Adding inavo to 1L fulv/palvo for high-risk PIK3CAm HR+/HER2- MBC improved PFS (17 vs 7 m) & OS (34 vs 27 mo), though low crossover to alpelisib (10%). Toxicities non-negligible. Concomitant @NEJM publication: https://t.co/Ugi320uOqL https://t.co/F3xpfpkdeM
12.8K impressions
Paolo Tarantino
@ptarantinomd
The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data. https://t.co/oNrmRNes0y
30.8K impressions
Dr Amol Akhade
@suyogcancer
Top 10 GI Trials – ASCO 2025 The biggest GI breakthroughs you must track this year! 🧬 ATOMIC – Atezolizumab + FOLFOX in stage III MSI-H colon 🛡️ MATTERHORN – Durvalumab + FLOT in gastric/GEJ 🧪 DYNAMIC-III – ctDNA-guided chemo in colon 💉 DESTINY-Gastric04 – T-DXd vs RAM+PTX https://t.co/QzeejEy9RN
26.5K impressions
Paolo Tarantino
@ptarantinomd
ASCENT-03 & -04 are positive: we may soon have the option of 1L SG (+/- pembro) for mTNBC. If TB02 is positive, we may also soon have Dato-DXd. ❓How will you treat a 50yo patient with TNBC (PD-L1-, IHC 1+) de novo metastatic to the lungs after progression on 1L SG (PFS 9 mo)?
22.3K impressions
Dr Amol Akhade
@suyogcancer
Top 10 Breast Cancer Trials to Watch at #ASCO25 Save the date ⏰ Big data in HER2+, TNBC & HR+ mBC! 1️⃣ DESTINY-Breast09 – T-DXd+P vs THP (1L HER2+ MBC) [LBA] 2️⃣ ASCENT-04 – SG+pembro vs chemo+pembro (1L TNBC) [LBA] 3️⃣ SERENA-6 – Camizestrant+CDK4/6i in ESR1mut HR+ ABC [LBA] 4️⃣ https://t.co/XFoBMbN7ab
19.9K impressions
OncoAlert
@oncoalert
The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 ⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB https://t.co/OEnYjYzvAN
19.8K impressions
NEJM
@nejm
Original Article: Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer (DESTINY-Gastric04 phase 3 trial) https://t.co/1HxEBJ8jvi #ASCO25 | @ASCO https://t.co/XMJSKDt2AM
14.8K impressions
Stephen V Liu, MD
@stephenvliu
Dr. @FordePatrick presents final OS results from CheckMate 816 at #ASCO25. Adding nivolumab to 3 cycles of neoadjuvant chemotherapy for resectable NSCLC improves OS with HR 0.72 and 5y OS rate 65% vs 55%. Effect greater in PDL1+ (HR 0.51) than PDL1 negative (HR 0.89). https://t.co/fK7scW7NtS
33.1K impressions
Paolo Tarantino
@ptarantinomd
ASCENT-03 & -04 are positive: we may soon have the option of 1L SG (+/- pembro) for mTNBC. If TB02 is positive, we may also soon have Dato-DXd. ❓How will you treat a 50yo patient with TNBC (PD-L1-, IHC 1+) de novo metastatic to the lungs after progression on 1L SG (PFS 9 mo)?
22.3K impressions
ASCO
@asco
5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - 2yr EFS 67% vs 59% (HR: 0.71). Improvement regardless of PDL1 - 2yr OS 76% vs 70%. mOS NR - Rate of✂️& number of FLOT similar in both arms - D-FLOT new SoC! https://t.co/tbMFPOK6oQ
12.0K impressions
Sara Tolaney
@stolaney1
ASCENT-03: SG superior to TPC chemo in 1L TNBC (PDL1- or IO ineligible) https://t.co/WJAWfDom2m
8.7K impressions
Dr Amol Akhade
@suyogcancer
🔥 NEW Targets & Modalities at #ASCO25 – DevTherapeutics Spotlight 1️⃣ B7-H4 ADC (Emi-Le) 2️⃣ PD-L1/4-1BB bispecific (LBL-024) 3️⃣ PRAME TCR-T (IMA203) 4️⃣ CLDN6×CD3 mRNA bispecific 5️⃣ KRAS G12D inhibitor 6️⃣ WT1 oral cancer vaccine 7️⃣ [²¹²Pb] VMT-α-NET 8️⃣ IL-2α-bias fusion Ab 9️⃣ https://t.co/fiRwp1qavn
7.8K impressions
Tom Powles
@tompowles1
At #ASCO25 : New Nectin4/PD1 combo data with response rates similar to EVP in bladder cancer. Also DV/toripalimab is better than chemo (press release). There multiple ways of beating 1st line chemo in UC. As chemo becomes less relevant a key question is around ADC sequencing https://t.co/7iUY4KWGCS
7.2K impressions
Ben Derman
@bdermanmd
🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇
11.0K impressions
Ben Derman
@bdermanmd
7500 – MIDAS Trial: MRD-Guided Therapy Post-IsaKRd 718 NDMM pts. After Isa-KRd x6, 67% were MRD− at 10⁻⁵. Randomized to continue Isa-KRd x 6 or go to ASCT prior to maintenance. No difference in MRD<10⁻6 (84% vs 86%) thus far! And as for MRD(+) post-induction: no difference https://t.co/W4NZuUVsIP
5.4K impressions
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽
@rfonsi1
The belle of the ball - long term follow up of CARTITUDE-1. One third rmeain alive and w/o progression at 5 years. 11 patients are MRD- at 10-6, possibly cured! (Denomitar varies if you substarct 5 patients lost to follow up or withdrew consent #ASCO25 https://t.co/6mf5qcuUBc
5.3K impressions
Vincent Rajkumar
@vincentrk
@PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri @bhemato @BerdejaJesus Re: CARTITUDE-1 my #1 pick #ASCO25 — In one center where serial MRD studies were done, all 12 pts progression free for ≥5 y were also MRD negative at 10–6 and imaging negative …
4.5K impressions
Ben Derman
@bdermanmd
MIDAS Trial: MRD-Guided Therapy Post-IsaKRd - The study was designed to understand the role of MRD negativity to guide decision-making around transplant in frontline myeloma. - After Isa-KRd x6, 67% were MRD− at 10⁻⁵. IThese patients were randomized to continue Isa-KRd x 6 https://t.co/OWOHqeFtJH
4.4K impressions
Hidehito HORINOUCHI
@hhorinouchi
🔄 #ASCO25 REVIEW🔁 ☑️#LCSM Rapid Oral, LocReg/SCLC 🔥AEGEAN: Association of post-surgical MRD status with neoadj ctDNA dynamics, genomic muts, and outcomes 🎙️ @MartinReck2 🎯No MRD-positive pts in the D arm had pCR or MPR @OncoAlert @ASCO @Larvol https://t.co/1adCy9xUmf https://t.co/DlXuKFtDz…
3.7K impressions
Vincent Rajkumar
@vincentrk
The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri
15.0K impressions
Ben Derman
@bdermanmd
🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇
11.0K impressions
Rahul Banerjee, MD, FACP
@rahulbanerjeemd
#ASCO25 And another one! @JCO_ASCO: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end for #plateauenvy? (cc @ninashah33) https://t.co…
5.1K impressions
Tom Powles
@tompowles1
Renal cancer #ASCO25 1) Casdatifan/carbo phase 2 data (RR=41%) ⏩️ R3 PEAK1 2)Biomarkers from sequential tissue from adjuvant atezo study IM010 3) CAR-T (CD70) data cRR20% 4) Final analysis for ipi/nivo ITT (HR 0.71) 5) predicting response to Cabo/nivo from TME & Microbiome https://t.co/waCKkHtLmq
4.8K impressions
Saad Z. Usmani MD MBA FACP 🇺🇸🇵
@szusmani
My top 5 picks for plasma cell disorders abstracts at #ASCO25 #mmsm in no order of preference: 1) 7505: Trispecific targeting BCMA/GPRC5D, this is by the far the most disruptive advance in early development! 2) 7507: Are we curing RRMM with BCMA CART? 3) 7508: Next Gen BCMA CART
2.5K impressions
Ben Derman
@bdermanmd
Tune in to hear about MRD-directed decision making, CAR T updates, and TRIspecific antibodies! https://t.co/LvF5BdPzHq
2.0K impressions
Adam Feuerstein ✡️
@adamfeuerstein
I deleted my previous $SMMT post because it was incorrect. Apologies. Corrected version here: $SMMT said ivonescimab PFS was stat sig and "consistent" between Chinese and western patient populations in HARMONi study. Overall surival HR 0.79 is not stat sig for the overall
13.7K impressions
Adam Feuerstein ✡️
@adamfeuerstein
Summit $SMMT -24% now. I updated my story. Summit is expected to present more specific data from the ivonescimab study at a future cancer research meeting, but for now, the sharp drop in the company's stock price reflects concern that "consistency" on tumor progression across
13.3K impressions
BowTiedBiotech 🧪🔬🧬
@bowtiedbiotech
🫁 Ivonescimab (PD1xVEGF) delivers a big PFS win in EGFR+ NSCLC $SMMT Post-osimertinib (EGFR TKI), options are limited, and PD-1s haven’t worked. But in HARMONi: 👉🏼 HR for PFS: 0.52 (p<0.00001) 👉🏼 OS trend: HR 0.79 (p=0.057) 👉🏼 Safety: Grade ≥3 AEs in 57% vs 50% 📉 Market https://t.co/U8yKWMeksF
12.0K impressions
Ben Derman
@bdermanmd
🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇
11.0K impressions
Rami Manochakian MD, FASCO Can
@rmanochakian
🔥🚨@OncoAlert Hot Off The Press Big #NewsRelease by @SMMT_TX in time with #ASCO25 Results from the #HARMONi Phase III global trial evaluating: #Ivonescimab + #Chemo vs #Chemo in pts with advanced #EGFR+ #NSCLC
7.9K impressions
Dr Amol Akhade
@suyogcancer
🔥 NEW Targets & Modalities at #ASCO25 – DevTherapeutics Spotlight 1️⃣ B7-H4 ADC (Emi-Le) 2️⃣ PD-L1/4-1BB bispecific (LBL-024) 3️⃣ PRAME TCR-T (IMA203) 4️⃣ CLDN6×CD3 mRNA bispecific 5️⃣ KRAS G12D inhibitor 6️⃣ WT1 oral cancer vaccine 7️⃣ [²¹²Pb] VMT-α-NET 8️⃣ IL-2α-bias fusion Ab 9️⃣ https://t.co/fiRwp1qavn
7.8K impressions
Dr Amol Akhade
@suyogcancer
🔥 NEW Targets & Modalities at #ASCO25 – DevTherapeutics Spotlight 1️⃣ B7-H4 ADC (Emi-Le) 2️⃣ PD-L1/4-1BB bispecific (LBL-024) 3️⃣ PRAME TCR-T (IMA203) 4️⃣ CLDN6×CD3 mRNA bispecific 5️⃣ KRAS G12D inhibitor 6️⃣ WT1 oral cancer vaccine 7️⃣ [²¹²Pb] VMT-α-NET 8️⃣ IL-2α-bias fusion Ab 9️⃣ https://t.co/fiRwp1qavn
7.8K impressions
Dr Amol Akhade
@suyogcancer
Thoracic Oncologists — Siena is here Don't feel sad as #ASCO25 has no lung cancer plenary. But these lung cancer trials are unmissable: ✨ CheckMate 77T – Periop nivo shines in resectable NSCLC 🎯 KRYSTAL-7 – Adagrasib + pembro in KRAS G12C ⚡ DeLLphi-304 – Tarlatamab moves https://t.co/gBCw51ZuMv
5.3K impressions
Stephen V Liu, MD
@stephenvliu
Dr. Pasi Janne at #ASCO25 with update on KRYSTAL7: phase II study of first line adagrasib plus pembrolizumab for #KRAS G12C NSCLC. RR 44% (61% for PDL1 high). mDOR 26.3m, PFS 11m (27.7m for PDL1 high), OS 18.3m. 17% had to stop pembro for TRAE. https://t.co/c4KhLlpOp5
3.6K impressions
Anirban Maitra
@aiims1742
#ASCO25 Kudos to the investigators for this positive phase 3 trial in locally advanced #PancreaticCancer. IMHO: Once orally bioavailable KRAS inhibitors plus chemo enter LAPC space in earnest, the modest improvement & QOL life issues of TTFs will make these results obsolete. https://t.co/eTRmtDN41J
3.1K impressions
Tom Newsom-Davis
@tnewsomdavis
KRYSTAL-7: Ada + Pembro, KRAS G12C NSCLC, Ph2 ✅ORR 44% ITT, 61% PD-L1 >50% ✅mPFS 11.0m ITT, 26.7m PD-L1 hi 🔹 By comparison, Pembro 7-8m, chemoIO 9m ✅mOS 18.3m, NR PD-L1 hi ❗️60% Gr3+ TRAE: GI & liver ❗️High dose redn & interr Active, AEs common, Ph3 ongoing #LCSM #ASCO25 https://t.co/JxWpl0dcJj
2.5K impressions
Dr Amol Akhade
@suyogcancer
🔥 KRYSTAL-7 Trial @ASCO25: ADA + PEMBRO in 1L KRAS G12C-mut NSCLC Dual blockade impresses, esp. in PD-L1 ≥50% group! Total (n=149): ORR: 44.3% mPFS: 11.0 mo mOS: 18.3 mo 18-mo OS: 51.8% PD-L1 <50% (n=95): ORR: 35.8% mPFS: 6.9 mo mOS: 15.5 mo 18-mo OS: 45.2% PD-L1
2.1K impressions
Top Tweets

The 10 tweets that defined ASCO 2025

Physician voices only, ranked by impressions. Click any card to open the original on X.

Vivek Subbiah, MD
@viveksubbiah
#1
🚨 Wow! #ASCO25 @ASCO was absolutely massive! 10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert
77.1K impressions
Bishal Gyawali, MD, PhD, FASCO
@oncology_bg
#2
The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial. https://t.co/bTgX1GS6Sr
56.9K impressions
Raffaele Colombo
@raffcolo
#3
#ASCO25 is in 4 weeks Here all the oral presentations on ADCs (one table with all the topo1, the other one with all the non-topo1, mainly MMAE) Trends: more topo1, earlier lines, combo, new indications! Usual suspects: payloads and targets! (Posters will follow, stay tuned) https://t.co/RzSs2VhdgU
48.2K impressions
Aaron Goodman - “Papa Heme”
@aarongoodman33
#4
The fact this was NOT a plenary at ASCO clearly demonstrates pharma’s strong influence over academic oncology in my opinion. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | New England Journal of Medicine https://t.co/5sksargPPo
45.5K impressions
Eric Topol
@erictopol
#5
The remarkable benefit of exercise was just extended to improved survival after cancer in a randomized trial @NEJM #ASCO25 https://t.co/rJXBq11wmC https://t.co/CrxoiTSVVY
45.2K impressions
Oncology Brothers
@oncbrothers
#6
< 2 wks to #ASCO25, here is a📝 of 🔑abstracts for general onc that could guide our SoC! - #ATOMIC - #MATTERHORN - #SERENA6 - #ASCENT04 - #DestinyBreast09 - #IMforte & #Dellphi304 - Updates: #CM816 &a…
37.9K impressions
Brad Loncar
@bradloncar
#7
People are going to see into the $SMMT data what they want to see. 1) East-West reproducibility on PFS and impressive HR are encouraging 2) Lack of success on OS so far potentially jeopardizes the entire hypothesis - wouldn't be the first time it has happened. Pick your side
36.5K impressions
Paolo Tarantino
@ptarantinomd
#8
One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm https://t.co/mJsp7aQ4fp
33.5K impressions
Stephen V Liu, MD
@stephenvliu
#9
Dr. @FordePatrick presents final OS results from CheckMate 816 at #ASCO25. Adding nivolumab to 3 cycles of neoadjuvant chemotherapy for resectable NSCLC improves OS with HR 0.72 and 5y OS rate 65% vs 55%. Effect greater in PDL1+ (HR 0.51) than PDL1 negative (HR 0.89). https://t.co/fK7scW7NtS
33.1K impressions
Paolo Tarantino
@ptarantinomd
#10
The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data. https://t.co/oNrmRNes0y
30.8K impressions
← Back to all conferences